pharmaceuticals

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATECYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"),…

1 week ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2025 16:42 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE)…

3 weeks ago
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage…

4 weeks ago
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…

1 month ago
Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred StockTitan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

April 11, 2025 16:15 ET  | Source: Titan Pharmaceuticals, Inc. NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals,…

1 month ago
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic ObesityRhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic Obesity

Company to host conference call on April 7 at 8 a.m. ET April 06, 2025 12:00 ET  | Source: Rhythm…

2 months ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 04, 2025 16:05 ET  | Source: Syndax Pharmaceuticals, Inc. NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals…

2 months ago
Atea Pharmaceuticals Issues Statement Regarding Director NominationsAtea Pharmaceuticals Issues Statement Regarding Director Nominations

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

No Shareholder Action is Required at this Time March 21, 2025 17:54 ET  | Source: Atea Pharmaceuticals, Inc. BOSTON, March…

2 months ago
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights PlanEagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

March 21, 2025 16:30 ET  | Source: Eagle Pharmaceuticals, Inc. WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle…

2 months ago
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Womens CancerZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer

March 15, 2025 11:25 ET  | Source: ZENTALIS PHARMACEUTICALS Azenosertib median duration of response (mDOR) updated to 6.3 months in…

2 months ago
Show more Posts